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To the Editor: Takahashi et al.1 have recently described the
effect of nicotinamide for controlling hyperphosphatemia in
dialysis patients. However, Rottembourg et al.2 reported
thrombocytopenia in the same setting. We have started a
prospective, open-label trial to study the efficiency and safety
of nicotinamide in our hemodialysis patients with resistant
hyperphosphatemia. Unlike Takahashi, we did not stop other
phosphate binders. Six patients have already been included.
Two patients were intolerant to sevelamer and thus only
treated with calcium carbonate. The other four patients
received a combined therapy. Five patients developed
diarrhea during the study. In two of them, it was so
important that nicotinamide had to be stopped. After
discontinuing nicotinamide, diarrhea disappeared. In the
three other patients, diarrhea improved with decreasing the
dose of nicotinamide. The diarrhea started at a mean dose of
10507447 mg. We observed a significant decrease in phosphat-
emia while on treatment (from 8578.7 to 54712.1 mg/l;
P¼ 0.0048 for the repeated measure analysis of variance),
but no effect on platelet count (from 260.167740.435
to 281.167751.503; P¼ 0.33).
Diarrhea induced by high doses of nicotinamide
is not described in non-renal failure population.3 However,
in Takahashi’s study, 7.8% of the patients developed such
an adverse effect.1 In our population, diarrhea induced
by nicotinamide might also be related to the simultaneous
use of calcium carbonate and/or sevelamer. If nicotinamide
proves to be useful in the management of hyperpho-
sphatemia, more studies are needed to evaluate its safety at
high doses.
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Tamm–Horsfall protein knockout
mice do not develop medullary
cystic kidney disease
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To the Editor: Medullary cystic kidney disease type 2
(MCKD2) and familial juvenile hyperuricemic nephropathy
(FJHN) are similar autosomal-dominant renal diseases with
shared features, including polyuria, progressive renal failure,
and abnormal urate handling, which leads to hyperuricemia
and gout. Both diseases are associated with corticomedullary
cysts, interstitial fibrosis secondary to infiltration by inflam-
matory cells, and marked thickening of tubular basement
membranes.1 Recent genetic studies in humans have shown
mutations in the UMOD (uromodulin, Tamm–Horsfall,
THP) gene in patients with MCKD2 and FJHN.2 It has been
suggested that MCKD2 and FJHN might represent different
forms of the same disease. Patients with the MCKD/FJHN
complex have also been shown to have reduced excretion of
THP in urine.3 It has remained unclear if changes of MCKD/
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Figure 1 | Renal Histology. (a and b) Kidney sections from THPþ /þ
and THP/ mice stained with hematoxylin and eosin, (c and d)
periodic acid schiff , and with (e and f) Masson’s trichrome (original
magnification  100). Renal histology was normal in all mice. There
were no areas of fibrosis or cystic change in the renal cortex or
medulla from either group of mice.
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